Driehaus Capital INDV Position
Active3-Fund ConvergenceDriehaus Capital increased their position in Indivior Pharmaceuticals, Inc. (INDV) in Q4 2025, holding $71.8M worth of shares across 2,000,339 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
INDV is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.
Full company profile →Short Interest
9.8%
3.9 days to cover
Driehaus Capital INDV Position History
Frequently Asked Questions
Does Driehaus Capital own INDV?
Yes. As of Q4 2025, Driehaus Capital holds 2,000,339 shares of Indivior Pharmaceuticals, Inc. (INDV) valued at $71.8M. This data comes from their SEC 13F filing.
How many hedge funds own INDV?
3 specialist biotech hedge funds currently hold INDV, including Deerfield Management, Rock Springs Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy INDV?
Driehaus Capital's position in INDV was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's INDV position increasing or decreasing?
Driehaus Capital increased their INDV position in the most recent quarter, adding 1,575,955 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
INDVCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →